Effects of the levonorgestrel-releasing intrauterine system on urinary symptoms in patients with adenomyosis

Murat Ekin, Huseyin Cengiz, Hüseyin Cengiz, Cengiz H, Ayağ ME, Mehmet Emin Ayağ, Cihan Kaya, Yasar L, Levent Yasar, Levent Yaşar, Savan K, Kadir Savan
European journal of obstetrics, gynecology, and reproductive biology · 2013 · vol. 170(2) , pp. 517–520 · doi:10.1016/j.ejogrb.2013.07.019 · PMID:23916583 · W2057819087
Non-randomised trial OA: closed CC0 ⤵ 12 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

This study investigated the impact of the levonorgestrel-releasing intrauterine system on urinary symptoms in patients diagnosed with adenomyosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVES: We hypothesized that treatment of adenomyosis with the levonorgestrel-releasing intrauterine system (LNG-IUS) can concurrently improve urinary incontinence along with irritative and obstructive symptoms and thus positively affect the patients' quality of life. STUDY DESIGN: Sixty-five patients suffering from heavy prolonged menstrual bleeding (menorrhagia) with dysmenorrhea diagnosed with uterine adenomyosis by ultrasound were enrolled in this study. LNG-IUS was inserted in the outpatient department for the treatment of the uterine adenomyosis. The patients filled out two validated questionnaires, the Urogenital Distress Inventory (UDI-6) and the Incontinence Impact Questionnaire (IIQ-7), before and 6 months after the insertion of the LNG-IUS. The before and after scores were compared using the non-parametric Mann-Whitney U test. RESULTS: The mean (± SD) age of the patients was 44.5 ± 6.5 years. Both UDI and IIQ scores were significantly lower at 6 months after treatment with the LNG-IUS (P<0.0001). UDI scores revealed improvement rates of 14.3%, 35.7%, and 22.7% for urinary incontinence, irritative symptoms, and obstructive symptoms, respectively. Moreover, improvements in irritative and obstructive symptoms were significantly correlated with improvements in menorrhagia and dysmenorrhea (P<0.04). IIQ scores demonstrated improvement rates of 18.9%, 14.6%, 19.7%, and 18.5% for physical activity, travel, social relations, and emotional health, respectively. CONCLUSIONS: LNG-IUS used for treating menorrhagia and dysmenorrhea improved urinary incontinence along with irritative and obstructive symptoms in patients with adenomyosis.

My notes (saved in your browser only)

Condition tags

adenomyosis

MeSH descriptors

Adenomyosis Contraceptive Agents, Female Intrauterine Devices Intrauterine Devices Levonorgestrel Urinary Incontinence Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adult Adult Contraceptive Agents, Female Contraceptive Agents, Female Female Female Humans Humans Levonorgestrel Levonorgestrel

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (22)

Cited by (12)

Source provenance

europepmc
last seen: 2026-10-17T06:09:56.316927+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:12:19.954899+00:00
unpaywall
last seen: 2026-10-17T06:24:38.187582+00:00
License: CC0 · commercial use OK